Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02287467 · ClinicalTrials.gov registry record · Phase 3
Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza
A Phase 3 study of Influenza a and Influenza B, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 329
- Enrollment target
- 20
- Study locations
NCT02287467: Completed Phase 3 study of Influenza a and Influenza B, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT02287467 is a Phase 3 study of Influenza a and Influenza B that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 329 participants, below the 2,721-participant average among 10 other Influenza a trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02287467, a Phase 3 study of Influenza a and Influenza B, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 329 participants
- Enrollment target
- 20
- Study locations
Study Summary
Influenza (the flu) is a common illness that usually occurs in autumn and winter. The flu is usually mild, but can cause serious illness or death. The purpose of this study is to test the safety and effectiveness of an antibody against the flu (called intravenous hyperimmune immunoglobulin or IVIG) in people who are hospitalized for severe flu.
Primary Outcome
This is the primary outcome, a 6-category ordinal outcome ranging from death (worst) to discharged from hospital with resumption of normal activities (best).
Conditions Studied
Interventions
- BIOLOGICAL Intravenous hyperimmune immunoglobulin (IVIG)
- BIOLOGICAL Placebo for IVIG
Study Locations (20)
Ohio
- Case Western Reserve University - Cleveland
- OHIO State University (OSU) Wexner Medical Center - Columbus
- Miami Valley Hospital - Dayton
Other
- Westmead Hospital - Sydney
- Odense University Hospital - Odense
- St James's University Hospital - Leeds
Minnesota
- Minneapolis VA Medical Center - Minneapolis
- Mayo Clinic - Rochester
New York
- Cornell CRS - New York
- Montefiore Medical Center - The Bronx
California
- UCSD Antiviral Research Center (A VRC) - San Diego
Colorado
- Denver Public Health - Denver
Illinois
- University of Illinois - Chicago
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 329 participants |
| Start Date | 2015-01 |
| Est. Completion | 2018-06-07 |
| Phase | Phase 3 |
What the finished NCT02287467 record still lists
NCT02287467 is an interventional study that assigns participants to a tested intervention. The registered 329 participants enrollment target is mid-sized for trials with a published cap, below the 2,721-participant average among 10 other Influenza a trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Influenza a appearing as the primary indexed condition, and to 2 interventions - of which Intravenous hyperimmune immunoglobulin (IVIG) is the first listed.
NCT02287467 names 20 study sites across 14 states, led by Ohio, Other, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02287467 about?
NCT02287467 is a clinical study titled "Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza". Influenza (the flu) is a common illness that usually occurs in autumn and winter. The flu is usually mild, but can cause serious illness or death. The purpose of this study is to test the safety and effectiveness of an antibody against the flu (called intravenous hyperimmune immunoglobulin or IVIG) ...
What is the current status of trial NCT02287467?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 329 participants. The study started on 2015-01. Estimated completion is 2018-06-07.
What conditions does trial NCT02287467 study?
This clinical trial studies the following conditions: Influenza a, Influenza B.
What interventions are being tested in trial NCT02287467?
The interventions under investigation include: Intravenous hyperimmune immunoglobulin (IVIG) (BIOLOGICAL), Placebo for IVIG (BIOLOGICAL).
Who is sponsoring clinical trial NCT02287467?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02287467 being conducted?
This trial has 20 study locations across California, Colorado, Illinois, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza a
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02287467's enrollment target sits among peer trials
329 7th of 10 higher than 4 of 10 other Influenza a trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza a trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV & COVID-19 Assay in Symptomatic Patients
RECRUITING · NA
-
A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines
COMPLETED · Phase 1
-
Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections
COMPLETED
-
Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7
COMPLETED · Phase 1
-
Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06036446 · 329 participants · NA
LATe Cerclage in High-risk Pregnancies (LATCH)
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia